Pacira BioSciences, Inc. (PCRX) News
Follow Pacira BioSciences, Inc. (PCRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary
Pacira BioSciences’ third-quarter revenue declined 2% year over year, while net income increased. EXPAREL and ZILRETTA sales rose, but lower iovera° sales and the absence of prior-year royalty revenue weighed on revenue;
EARNINGS | Nov 05, 2026, 09:42 PM UTC
M
Viatris Commences Tender Offer to Acquire Pacira BioSciences
EQUITY | Oct 30, 2026, 01:03 PM UTC
M
Viatris Agrees to Buy Pacira BioSciences for $1.65 Billion
Viatris said it agreed to acquire Pacira BioSciences for $1.65 billion in cash.
MNA | Oct 12, 2026, 06:32 AM UTC
H
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris Inc. (NASDAQ: VTRS ) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ: PCRX ) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris
LIVE | Oct 08, 2026, 04:49 PM UTC
H
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.39% to 50,978.59 while the NASDAQ declined 0.61% to 27,371.84. The S&P 500 also fell,
LIVE | Oct 08, 2026, 04:03 PM UTC
H
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Thursday. Shares of Helen of Troy Limited (NASDAQ: HELE ) rose sharply after the company reported better-than-expected second-quarter adjuste
LIVE | Oct 08, 2026, 01:53 PM UTC
M
Pacira to pay Viatris $62 million termination fee
Pacira BioSciences will pay Viatris a $62 million termination fee under specified circumstances, per the reported agreement terms.
EQUITY | Oct 08, 2026, 01:04 PM UTC
M
Viatris agrees to acquire Pacira BioSciences
EQUITY | Oct 08, 2026, 11:56 AM UTC
L
Pacira BioSciences Price Target Announced at $32.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) Pacira BioSciences Initiated at Outperform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 10:43 AM UTC
L
Leerink Partners sets Pacira Biosciences price target at $28
Leerink Partners announced a $28.00/share price target for Pacira Biosciences (PCRX).
EQUITY | Sep 09, 2026, 03:31 PM UTC
L
Pacira BioSciences grants inducement awards under Nasdaq Rule 5635(c)(4)
Pacira BioSciences said it granted inducement awards on September 2, 2026 to five new employees, pursuant to Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 09, 2026, 12:03 PM UTC
L
Pacira BioSciences reports inducement grants under Nasdaq Rule 5635(c)(4)
Pacira BioSciences (PCRX) reported inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Sep 09, 2026, 12:00 PM UTC
L
PharmaCorp Rx Inc. Announces Board and Committee Changes
PharmaCorp Rx Inc. Announces Board and Committee Changes
EQUITY | Aug 27, 2026, 11:37 AM UTC
H
Pacira BioSciences Publishes Positive PCRX-201 Data
Pacira BioSciences publishes positive two-year phase 1 data
EQUITY | Aug 06, 2026, 12:00 PM UTC
L
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ: PCRX ) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
EARNINGS | Aug 04, 2026, 08:03 PM UTC
L
PCRX - Pacira BioSciences Reports Second Quarter 2026 Financial Results
PCRX - Pacira BioSciences Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:01 PM UTC
L
PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update
Eight pharmacies acquired at an aggregate
MNA | Jul 06, 2026, 11:30 AM UTC
L
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ: PCRX ) with a Buy and maintains $38 price target.
EQUITY | Jul 01, 2026, 12:15 PM UTC
L
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outp
- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX ), the industry leader in its c
EQUITY | Jul 01, 2026, 12:02 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC